Does the media prefer DYN or WVE?

In the previous week, Dyne Therapeutics and Dyne Therapeutics both had 15 articles in the media. WAVE Life Sciences' average media sentiment score of 0.35 beat Dyne Therapeutics' score of 0.15 indicating that WAVE Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyne Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral WAVE Life Sciences 3 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts prefer GMTX or WVE?

WAVE Life Sciences has a consensus price target of $21.65, indicating a potential upside of 470.41%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe WAVE Life Sciences is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 WAVE Life Sciences 1 Sell rating(s) 2 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 2.78

Which has better valuation and earnings, WVE or ZLAB?

Zai Lab has higher revenue and earnings than WAVE Life Sciences. Zai Lab is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio WAVE Life Sciences $42.73M 17.50 -$204.38M -$1.09 N/A Zai Lab $460.16M 6.03 -$175.54M -$1.71 N/A

Is WVE or ZLAB more profitable?

Zai Lab has a net margin of -41.86% compared to WAVE Life Sciences' net margin of -309.73%. Zai Lab's return on equity of -27.43% beat WAVE Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets WAVE Life Sciences -309.73% -50.36% -40.06% Zai Lab -41.86% -27.43% -16.72%

Does the media favor WVE or ZLAB?

In the previous week, WAVE Life Sciences had 11 more articles in the media than Zai Lab. MarketBeat recorded 15 mentions for WAVE Life Sciences and 4 mentions for Zai Lab. WAVE Life Sciences' average media sentiment score of 0.35 beat Zai Lab's score of -0.33 indicating that WAVE Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment WAVE Life Sciences 3 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Zai Lab 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has better earnings & valuation, WVE or PGEN?

WAVE Life Sciences has higher revenue and earnings than Precigen. Precigen is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio WAVE Life Sciences $42.73M 17.50 -$204.38M -$1.09 N/A Precigen $9.68M 305.10 -$250.64M -$1.04 N/A

Is WVE or PGEN more profitable?

Precigen has a net margin of -183.98% compared to WAVE Life Sciences' net margin of -309.73%. Precigen's return on equity of 423.75% beat WAVE Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets WAVE Life Sciences -309.73% -50.36% -40.06% Precigen -183.98% 423.75% 84.39%

Does the media favor WVE or PGEN?

In the previous week, WAVE Life Sciences had 1 more articles in the media than Precigen. MarketBeat recorded 15 mentions for WAVE Life Sciences and 14 mentions for Precigen. Precigen's average media sentiment score of 0.69 beat WAVE Life Sciences' score of 0.35 indicating that Precigen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment WAVE Life Sciences 3 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Precigen 3 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor NAMS or WVE?

In the previous week, WAVE Life Sciences had 9 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 15 mentions for WAVE Life Sciences and 6 mentions for NewAmsterdam Pharma. WAVE Life Sciences' average media sentiment score of 0.35 beat NewAmsterdam Pharma's score of 0.14 indicating that WAVE Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewAmsterdam Pharma 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral WAVE Life Sciences 3 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

WAVE Life Sciences (WVE) Competitors

$3.78 -0.10 (-2.58%)

Closing price 04:00 PM Eastern

Extended Trading

$3.85 +0.07 (+1.96%)

As of 07:40 PM Eastern

Compare

WVE vs. DYN, GMTX, ZLAB, PGEN, and NAMS

Should you buy WAVE Life Sciences stock or one of its competitors? WAVE Life Sciences's main competitors and comparable companies include Dyne Therapeutics (DYN), Gemini Therapeutics (GMTX), Zai Lab (ZLAB), Precigen (PGEN), and NewAmsterdam Pharma (NAMS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does WAVE Life Sciences compare to Dyne Therapeutics?

Dyne Therapeutics (NASDAQ:DYN) and WAVE Life Sciences (NASDAQ:WVE) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.

In the previous week, Dyne Therapeutics and Dyne Therapeutics both had 15 articles in the media. WAVE Life Sciences' average media sentiment score of 0.35 beat Dyne Therapeutics' score of 0.15 indicating that WAVE Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyne Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
WAVE Life Sciences	3 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

96.7% of Dyne Therapeutics shares are held by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are held by institutional investors. 9.5% of Dyne Therapeutics shares are held by insiders. Comparatively, 24.3% of WAVE Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

WAVE Life Sciences has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.33	N/A
WAVE Life Sciences	$42.73M	17.50	-$204.38M	-$1.09	N/A

Dyne Therapeutics has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.42, meaning that its stock price is 242% less volatile than the broader market.

Dyne Therapeutics presently has a consensus price target of $33.07, suggesting a potential upside of 112.95%. WAVE Life Sciences has a consensus price target of $21.65, suggesting a potential upside of 470.41%. Given WAVE Life Sciences' higher possible upside, analysts clearly believe WAVE Life Sciences is more favorable than Dyne Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.82
WAVE Life Sciences	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78

Dyne Therapeutics has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -309.73%. WAVE Life Sciences' return on equity of -50.36% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-64.30%	-50.33%
WAVE Life Sciences	-309.73%	-50.36%	-40.06%

Summary

WAVE Life Sciences beats Dyne Therapeutics on 10 of the 15 factors compared between the two stocks.

How does WAVE Life Sciences compare to Gemini Therapeutics?

Gemini Therapeutics (NASDAQ:GMTX) and WAVE Life Sciences (NASDAQ:WVE) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation.

Gemini Therapeutics has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -309.73%. Gemini Therapeutics' return on equity of -38.78% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gemini Therapeutics	N/A	-38.78%	-35.88%
WAVE Life Sciences	-309.73%	-50.36%	-40.06%

WAVE Life Sciences has a consensus price target of $21.65, indicating a potential upside of 470.41%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe WAVE Life Sciences is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
WAVE Life Sciences	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78

In the previous week, WAVE Life Sciences had 15 more articles in the media than Gemini Therapeutics. MarketBeat recorded 15 mentions for WAVE Life Sciences and 0 mentions for Gemini Therapeutics. WAVE Life Sciences' average media sentiment score of 0.35 beat Gemini Therapeutics' score of 0.00 indicating that WAVE Life Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Gemini Therapeutics	Neutral
WAVE Life Sciences	Neutral

Gemini Therapeutics has a beta of -0.12, meaning that its share price is 112% less volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.42, meaning that its share price is 242% less volatile than the broader market.

75.4% of Gemini Therapeutics shares are owned by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by insiders. Comparatively, 24.3% of WAVE Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Gemini Therapeutics has higher earnings, but lower revenue than WAVE Life Sciences. Gemini Therapeutics is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A
WAVE Life Sciences	$42.73M	17.50	-$204.38M	-$1.09	N/A

Summary

WAVE Life Sciences beats Gemini Therapeutics on 9 of the 15 factors compared between the two stocks.

How does WAVE Life Sciences compare to Zai Lab?

WAVE Life Sciences (NASDAQ:WVE) and Zai Lab (NASDAQ:ZLAB) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

Zai Lab has higher revenue and earnings than WAVE Life Sciences. Zai Lab is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
WAVE Life Sciences	$42.73M	17.50	-$204.38M	-$1.09	N/A
Zai Lab	$460.16M	6.03	-$175.54M	-$1.71	N/A

In the previous week, WAVE Life Sciences had 11 more articles in the media than Zai Lab. MarketBeat recorded 15 mentions for WAVE Life Sciences and 4 mentions for Zai Lab. WAVE Life Sciences' average media sentiment score of 0.35 beat Zai Lab's score of -0.33 indicating that WAVE Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
WAVE Life Sciences	3 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Zai Lab	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Zai Lab has a net margin of -41.86% compared to WAVE Life Sciences' net margin of -309.73%. Zai Lab's return on equity of -27.43% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
WAVE Life Sciences	-309.73%	-50.36%	-40.06%
Zai Lab	-41.86%	-27.43%	-16.72%

89.7% of WAVE Life Sciences shares are held by institutional investors. Comparatively, 41.7% of Zai Lab shares are held by institutional investors. 24.3% of WAVE Life Sciences shares are held by insiders. Comparatively, 4.9% of Zai Lab shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

WAVE Life Sciences presently has a consensus target price of $21.65, indicating a potential upside of 470.41%. Zai Lab has a consensus target price of $37.25, indicating a potential upside of 52.70%. Given WAVE Life Sciences' stronger consensus rating and higher probable upside, equities analysts plainly believe WAVE Life Sciences is more favorable than Zai Lab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
WAVE Life Sciences	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

WAVE Life Sciences has a beta of -1.42, indicating that its share price is 242% less volatile than the broader market. Comparatively, Zai Lab has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market.

Summary

WAVE Life Sciences beats Zai Lab on 10 of the 17 factors compared between the two stocks.

How does WAVE Life Sciences compare to Precigen?

WAVE Life Sciences (NASDAQ:WVE) and Precigen (NASDAQ:PGEN) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

89.7% of WAVE Life Sciences shares are held by institutional investors. Comparatively, 33.5% of Precigen shares are held by institutional investors. 24.3% of WAVE Life Sciences shares are held by company insiders. Comparatively, 41.4% of Precigen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Precigen has a net margin of -183.98% compared to WAVE Life Sciences' net margin of -309.73%. Precigen's return on equity of 423.75% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
WAVE Life Sciences	-309.73%	-50.36%	-40.06%
Precigen	-183.98%	423.75%	84.39%

WAVE Life Sciences has higher revenue and earnings than Precigen. Precigen is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
WAVE Life Sciences	$42.73M	17.50	-$204.38M	-$1.09	N/A
Precigen	$9.68M	305.10	-$250.64M	-$1.04	N/A

WAVE Life Sciences has a beta of -1.42, meaning that its share price is 242% less volatile than the broader market. Comparatively, Precigen has a beta of 0.92, meaning that its share price is 8% less volatile than the broader market.

In the previous week, WAVE Life Sciences had 1 more articles in the media than Precigen. MarketBeat recorded 15 mentions for WAVE Life Sciences and 14 mentions for Precigen. Precigen's average media sentiment score of 0.69 beat WAVE Life Sciences' score of 0.35 indicating that Precigen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
WAVE Life Sciences	3 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Precigen	3 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

WAVE Life Sciences currently has a consensus target price of $21.65, indicating a potential upside of 470.41%. Precigen has a consensus target price of $13.67, indicating a potential upside of 64.98%. Given WAVE Life Sciences' higher probable upside, research analysts plainly believe WAVE Life Sciences is more favorable than Precigen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
WAVE Life Sciences	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78
Precigen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

Precigen beats WAVE Life Sciences on 10 of the 17 factors compared between the two stocks.

How does WAVE Life Sciences compare to NewAmsterdam Pharma?

NewAmsterdam Pharma (NASDAQ:NAMS) and WAVE Life Sciences (NASDAQ:WVE) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership, media sentiment and dividends.

NewAmsterdam Pharma has higher earnings, but lower revenue than WAVE Life Sciences. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$22.50M	123.41	-$203.82M	-$2.16	N/A
WAVE Life Sciences	$42.73M	17.50	-$204.38M	-$1.09	N/A

NewAmsterdam Pharma has a beta of 0.1, indicating that its share price is 90% less volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.42, indicating that its share price is 242% less volatile than the broader market.

In the previous week, WAVE Life Sciences had 9 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 15 mentions for WAVE Life Sciences and 6 mentions for NewAmsterdam Pharma. WAVE Life Sciences' average media sentiment score of 0.35 beat NewAmsterdam Pharma's score of 0.14 indicating that WAVE Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NewAmsterdam Pharma	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
WAVE Life Sciences	3 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

NewAmsterdam Pharma currently has a consensus target price of $49.73, indicating a potential upside of 114.08%. WAVE Life Sciences has a consensus target price of $21.65, indicating a potential upside of 470.41%. Given WAVE Life Sciences' higher probable upside, analysts plainly believe WAVE Life Sciences is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
WAVE Life Sciences	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78

WAVE Life Sciences has a net margin of -309.73% compared to NewAmsterdam Pharma's net margin of -3,644.21%. NewAmsterdam Pharma's return on equity of -34.81% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	-3,644.21%	-34.81%	-31.50%
WAVE Life Sciences	-309.73%	-50.36%	-40.06%

89.9% of NewAmsterdam Pharma shares are held by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are held by institutional investors. 12.7% of NewAmsterdam Pharma shares are held by insiders. Comparatively, 24.3% of WAVE Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

WAVE Life Sciences beats NewAmsterdam Pharma on 9 of the 17 factors compared between the two stocks.

Get WAVE Life Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding WVE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

WVE vs. The Competition

Export

Metric	WAVE Life Sciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$764.55M	$3.87B	$7.14B	$13.10B
Dividend Yield	N/A	3.65%	2.54%	16.76%
P/E Ratio	-3.47	7.65	214.49	21.54
Price / Sales	11.39	1,292.25	607.75	91.81
Price / Cash	N/A	122.60	77.60	51.75
Price / Book	1.22	16.63	10.92	6.30
Net Income	-$204.38M	-$22.67M	$3.50B	$361.43M
7 Day Performance	N/A	-3.05%	-2.11%	-1.67%
1 Month Performance	-22.54%	-10.75%	-6.34%	-3.94%
1 Year Performance	-46.15%	21.11%	8.81%	2.77%

WAVE Life Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
WVE WAVE Life Sciences	2.8994 of 5 stars	$3.78 -2.6%	$21.65 +472.7%	-44.8%	$764.55M	$65.37M	N/A	317	News Coverage Analyst Forecast
DYN Dyne Therapeutics	3.3585 of 5 stars	$16.03 -2.9%	$32.17 +100.7%	+26.6%	$3.08B	N/A	N/A	258	Analyst Forecast Analyst Revision
GMTX Gemini Therapeutics	N/A	$66.44 +0.5%	N/A	-0.9%	$2.88B	N/A	N/A	30	High Trading Volume
ZLAB Zai Lab	1.8346 of 5 stars	$24.98 -1.2%	$37.25 +49.1%	-26.0%	$2.88B	$460.16M	N/A	1,784	Gap Down
PGEN Precigen	3.8799 of 5 stars	$7.75 +0.6%	$13.67 +76.3%	+145.8%	$2.75B	$9.68M	N/A	47

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:WVE) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

WAVE Life Sciences (WVE) Competitors

WVE vs. DYN, GMTX, ZLAB, PGEN, and NAMS

How does WAVE Life Sciences compare to Dyne Therapeutics?

Summary

How does WAVE Life Sciences compare to Gemini Therapeutics?

Summary

How does WAVE Life Sciences compare to Zai Lab?

Summary

How does WAVE Life Sciences compare to Precigen?

Summary

How does WAVE Life Sciences compare to NewAmsterdam Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WVE vs. The Competition

WAVE Life Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

WAVE Life Sciences (WVE) Competitors

WVE vs. DYN, GMTX, ZLAB, PGEN, and NAMS

How does WAVE Life Sciences compare to Dyne Therapeutics?

Does the media prefer DYN or WVE?

Do institutionals & insiders hold more shares of DYN or WVE?

Which has better valuation & earnings, DYN or WVE?

Which has more volatility & risk, DYN or WVE?

Do analysts recommend DYN or WVE?

Is DYN or WVE more profitable?

Summary

How does WAVE Life Sciences compare to Gemini Therapeutics?

Is GMTX or WVE more profitable?

Do analysts prefer GMTX or WVE?

Does the media favor GMTX or WVE?

Which has more volatility and risk, GMTX or WVE?

Do institutionals & insiders believe in GMTX or WVE?

Which has better earnings & valuation, GMTX or WVE?

Summary

How does WAVE Life Sciences compare to Zai Lab?

Which has better valuation and earnings, WVE or ZLAB?

Does the media favor WVE or ZLAB?

Is WVE or ZLAB more profitable?

Do institutionals & insiders believe in WVE or ZLAB?

Do analysts rate WVE or ZLAB?

Which has more risk and volatility, WVE or ZLAB?

Summary

How does WAVE Life Sciences compare to Precigen?

Do insiders and institutionals have more ownership in WVE or PGEN?

Is WVE or PGEN more profitable?

Which has better earnings & valuation, WVE or PGEN?

Which has more volatility and risk, WVE or PGEN?

Does the media favor WVE or PGEN?

Do analysts recommend WVE or PGEN?

Summary

How does WAVE Life Sciences compare to NewAmsterdam Pharma?

Which has better valuation & earnings, NAMS or WVE?

Which has more risk and volatility, NAMS or WVE?

Does the media favor NAMS or WVE?

Do analysts recommend NAMS or WVE?

Is NAMS or WVE more profitable?

Do insiders & institutionals have more ownership in NAMS or WVE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WVE vs. The Competition

WAVE Life Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools